Literature DB >> 18993004

New horizons in prostate cancer imaging.

Gregory Ravizzini1, Baris Turkbey, Karen Kurdziel, Peter L Choyke.   

Abstract

Prostate cancer is the most common non-cutaneous malignancy among American men. Imaging has recently become more important in detection of prostate cancer since screening techniques such as digital rectal examination (DRE), prostate specific and transrectal ultrasound guided biopsy have considerable limitations in diagnosis and localization of prostate cancer. In this manuscript, we reviewed conventional, functional and targeted imaging modalities used in diagnosis and local staging of prostate cancer with exquisite images.

Entities:  

Mesh:

Year:  2008        PMID: 18993004      PMCID: PMC2702141          DOI: 10.1016/j.ejrad.2008.09.019

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  97 in total

1.  On the origin of cancer cells.

Authors:  O WARBURG
Journal:  Science       Date:  1956-02-24       Impact factor: 47.728

2.  Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma.

Authors:  David M Schuster; John R Votaw; Peter T Nieh; Weiping Yu; Jonathon A Nye; Viraj Master; F DuBois Bowman; Muta M Issa; Mark M Goodman
Journal:  J Nucl Med       Date:  2007-01       Impact factor: 10.057

Review 3.  Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view.

Authors:  C Andrew Boswell; Martin W Brechbiel
Journal:  Nucl Med Biol       Date:  2007-06-08       Impact factor: 2.408

4.  Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy.

Authors:  C Hofer; C Laubenbacher; T Block; J Breul; R Hartung; M Schwaiger
Journal:  Eur Urol       Date:  1999       Impact factor: 20.096

5.  Prostate cancer: prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging.

Authors:  K K Yu; J Scheidler; H Hricak; D B Vigneron; C J Zaloudek; R G Males; S J Nelson; P R Carroll; J Kurhanewicz
Journal:  Radiology       Date:  1999-11       Impact factor: 11.105

6.  18F-fluoroacetate: a potential acetate analog for prostate tumor imaging--in vivo evaluation of 18F-fluoroacetate versus 11C-acetate.

Authors:  Datta E Ponde; Carmen S Dence; Nobuyuki Oyama; Joonyoung Kim; Yuan-Chuan Tai; Richard Laforest; Barry A Siegel; Michael J Welch
Journal:  J Nucl Med       Date:  2007-03       Impact factor: 10.057

7.  Immunoscintigraphy with indium-111-capromab pendetide: evaluation before definitive therapy in patients with prostate cancer.

Authors:  M J Manyak; G H Hinkle; J O Olsen; R P Chiaccherini; A W Partin; S Piantadosi; J K Burgers; J H Texter; C E Neal; J A Libertino; G L Wright; R T Maguire
Journal:  Urology       Date:  1999-12       Impact factor: 2.649

8.  Impact of additional sampling in the TRUS-guided biopsy for the diagnosis of prostate cancer.

Authors:  Konstantinos Stamatiou; Alevizos Alevizos; Vasilisa Karanasiou; Anargiros Mariolis; Constantinos Mihas; Marek Papathanasiou; Konstantinos Bovis; Frangiskos Sofras
Journal:  Urol Int       Date:  2007       Impact factor: 2.089

9.  Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study.

Authors:  Mohsen Beheshti; Reza Vali; Peter Waldenberger; Friedrich Fitz; Michael Nader; Wolfgang Loidl; Gabriele Broinger; Franz Stoiber; Ignac Foglman; Werner Langsteger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-05-09       Impact factor: 9.236

10.  Constitutive and antibody-induced internalization of prostate-specific membrane antigen.

Authors:  H Liu; A K Rajasekaran; P Moy; Y Xia; S Kim; V Navarro; R Rahmati; N H Bander
Journal:  Cancer Res       Date:  1998-09-15       Impact factor: 12.701

View more
  18 in total

1.  Pretargeted immunoPET of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody in mice with PC3 xenografts.

Authors:  Catharina M van Rij; Cathelijne Frielink; David M Goldenberg; Robert M Sharkey; Gerben M Franssen; Susanne Lütje; William J McBride; Wim J G Oyen; Otto C Boerman
Journal:  Mol Imaging Biol       Date:  2015-02       Impact factor: 3.488

2.  Nanoparticle PET/CT imaging of natriuretic peptide clearance receptor in prostate cancer.

Authors:  Eric D Pressly; Richard A Pierce; Luke A Connal; Craig J Hawker; Yongjian Liu
Journal:  Bioconjug Chem       Date:  2013-01-11       Impact factor: 4.774

3.  Magnetic resonance imaging for prostate cancer clinical application.

Authors:  Bing Li; Yong Du; Hanfeng Yang; Yayong Huang; Jun Meng; Dongmei Xiao
Journal:  Chin J Cancer Res       Date:  2013-04       Impact factor: 5.087

4.  Usefulness of MRI-assisted metabolic volumetric parameters provided by simultaneous (18)F-fluorocholine PET/MRI for primary prostate cancer characterization.

Authors:  Yong-Il Kim; Gi Jeong Cheon; Jin Chul Paeng; Jeong Yeon Cho; Cheol Kwak; Keon Wook Kang; June-Key Chung; Euishin Edmund Kim; Dong Soo Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-03-11       Impact factor: 9.236

5.  Clinical significance of incidental FDG uptake in the prostate gland detected by PET/CT.

Authors:  Ertan Sahin; Umut Elboga; Ebuzer Kalender; Mustafa Basıbuyuk; Hasan Deniz Demir; Yusuf Zeki Celen
Journal:  Int J Clin Exp Med       Date:  2015-07-15

6.  [Type and extent of preoperative imaging before radical prostatectomy].

Authors:  H Isbarn; S Kellermann; G Salomon; T Steuber; H Huland; M Graefen
Journal:  Urologe A       Date:  2010-03       Impact factor: 0.639

Review 7.  Update on prostate imaging.

Authors:  Jalil Afnan; Clare M Tempany
Journal:  Urol Clin North Am       Date:  2010-02       Impact factor: 2.241

8.  [Imaging diagnostics of advanced prostate cancer].

Authors:  A Kretschmer; M Seitz; A Graser; C G Stief; D Tilki
Journal:  Urologe A       Date:  2013-04       Impact factor: 0.639

9.  An integrated approach to identify normal tissue expression of targets for antibody-drug conjugates: case study of TENB2.

Authors:  C Andrew Boswell; Eduardo E Mundo; Ron Firestein; Crystal Zhang; Weiguang Mao; Herman Gill; Cynthia Young; Nina Ljumanovic; Shannon Stainton; Sheila Ulufatu; Aimee Fourie; Katherine R Kozak; Reina Fuji; Paul Polakis; Leslie A Khawli; Kedan Lin
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

10.  Pretargeted immuno-PET and radioimmunotherapy of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody.

Authors:  Catharina M van Rij; Susanne Lütje; Cathelijne Frielink; Robert M Sharkey; David M Goldenberg; Gerben M Franssen; William J McBride; Edmund A Rossi; Wim J G Oyen; Otto C Boerman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05-15       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.